EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Malignant Mesothelioma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Yervoy (ipilimumab)

Snippet

Status: Authorised. Therapeutic area: Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 13/11/2025